Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors Journal Article

   


Authors: Salz, T.; Zabor, E. C.; Brown, P. D. N.; Dalton, S. O.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Hjalgrim, H.; Specht, L.; Vickers, A. J.; Oeffinger, K. C.; Johansen, C.
Article Title: Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors
Abstract: Background: Mediastinal radiation is associated with increased risk of myocardial infarction (MI) among non-Hodgkin lymphoma (NHL) survivors. Objective: To evaluate how preexisting cardiovascular risk factors (CVRFs) modify the association of mediastinal radiation and MI among a national population of NHL survivors with a range of CVRFs. Material and methods: Using Danish registries, we identified adults diagnosed with lymphoma 2000–2010. We assessed MI from one year after diagnosis through 2016. We ascertained CVRFs (hypertension, dyslipidemia, and diabetes), vascular disease, and intrinsic heart disease prevalent at lymphoma diagnosis. We used multivariable Cox regression to test the interaction between preexisting CVRFs and receipt of mediastinal radiation on subsequent MI. Results: Among 3151 NHL survivors (median age 63, median follow-up 6.5 years), 96 were diagnosed with MI. Before lymphoma, 32% of survivors had ≥1 CVRF. 8.5% of survivors received mediastinal radiation. In multivariable analysis, we found that mediastinal radiation (HR = 1.96; 95% CI = 1.09–3.52), and presence of ≥1 CVRF (HR = 2.71; 95% CI = 1.77–4.15) were associated with an increased risk of MI. Although there was no interaction on the relative scale (p = 0.14), we saw a clinically relevant absolute increase in risk for patients with CVRF from 10-year of MI of 10.5% without radiation to 29.5% for those undergoing radiation. Conclusion: Patients with CVRFs have an importantly higher risk of subsequent MI if they have mediastinal radiation. Routine evaluation of CVRFs and optimal treatment of preexisting cardiovascular disease should continue after receiving cancer therapy. In patients with CVRFs, mediastinal radiation should only be given if oncologic benefit clearly outweighs cardiovascular harm. © 2022 Acta Oncologica Foundation.
Keywords: adult; cancer survival; controlled study; aged; middle aged; major clinical study; hypertension; outcome assessment; follow up; risk factors; risk factor; survivor; cancer survivor; risk assessment; survivors; nonhodgkin lymphoma; lymphoma, non-hodgkin; cardiovascular disease; heart infarction; cardiovascular diseases; diabetes mellitus; lymphoma; radiation therapy; antihypertensive agent; dyslipidemia; anthracycline; beta adrenergic receptor blocking agent; calcium channel blocking agent; hydroxymethylglutaryl coenzyme a reductase inhibitor; diuretic agent; myocardial infarction; angiotensin receptor antagonist; alpha adrenergic receptor blocking agent; cardiovascular risk factor; cancer survivorship; humans; human; male; female; article; heart disease risk factors
Journal Title: Acta Oncologica
Volume: 61
Issue: 9
ISSN: 0284-186X
Publisher: Informa Healthcare  
Date Published: 2022-01-01
Start Page: 1064
End Page: 1068
Language: English
DOI: 10.1080/0284186x.2022.2107402
PUBMED: 36256902
PROVIDER: scopus
PMCID: PMC9888465
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140110063&doi=10.1080%2f0284186X.2022.2107402&partnerID=40&md5=91995b84daed670e06f3c736fede8f1a
Notes: Article -- Export Date: 1 December 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Talya Salz
    68 Salz
  2. Richard M Steingart
    175 Steingart
  3. Andrew J Vickers
    884 Vickers
  4. Matthew J Matasar
    290 Matasar
  5. Nirupa Jaya Raghunathan
    38 Raghunathan
Related MSK Work